clofibric acid has been researched along with Coronary Heart Disease in 38 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids." | 4.84 | Hypertriglyceridemia and cardiovascular risk reduction. ( Jacobson, TA; Miller, M; Schaefer, EJ, 2007) |
| "Niacin treatment (alone) was compared with etofibrate and niacin combination to treat patients with high-density lipoprotein <35 mg/dl and without hypertriglyceridemia." | 2.69 | Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl. ( Caramelli, B; Mansur, AP; Ramires, JA; Serrano, CV; Spósito, AC, 1999) |
| "Clofibric acid was only effective in reducing triglycerides." | 2.67 | Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. ( Dude, H; Fischer, S; Hanefeld, M; Julius, U; Rothe, G; Schmechel, H; Schulze, J; Schwanebeck, U, 1991) |
| "The niacin model was moderately different from the statin model (K = 7." | 2.45 | Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. ( Jacobson, TA; Robinson, JG; Smith, BJ; Wang, S, 2009) |
| "Coronary heart disease is a major cause of mortality in women in Western industrialised countries, particularly after the age of 50 years, coinciding with the onset of the menopause and potentially adverse metabolic changes that occur during the transitional peri-menopausal and post-menopausal periods." | 2.44 | HDL-C in post-menopausal women: An important therapeutic target. ( Collins, P, 2008) |
| "Niacin has a more potent effect on HDL-C levels, whereas data on cardiovascular event rate reduction are limited." | 2.43 | Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. ( Birjmohun, RS; Hutten, BA; Kastelein, JJ; Stroes, ES, 2005) |
| " Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates." | 2.43 | Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. ( Davidson, MH, 2006) |
| "Dyslipidaemia in patients with type 2 diabetes commonly consists of elevated triglyceride levels; normal or slightly elevated low-density lipoprotein (LDL)-cholesterol levels with a preponderance of small, dense LDL particles; and low high-density lipoprotein (HDL)-cholesterol levels with a preponderance of small, dense HDL." | 2.42 | LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit? ( Taskinen, MR, 2003) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance." | 2.39 | Drug interactions with fibric acids. ( Dujovne, CA; Lozada, A, 1994) |
| "Likewise, the metabolic syndrome is a secondary target of treatment." | 1.32 | CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management. ( Thompson, PD, 2003) |
| "Bezafibrate is a potent lipid-lowering agent of the new generation." | 1.26 | Clinical experience with bezafibrate. ( Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.53) | 18.7374 |
| 1990's | 5 (13.16) | 18.2507 |
| 2000's | 28 (73.68) | 29.6817 |
| 2010's | 1 (2.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tovar, JM | 1 |
| Bazaldua, OV | 1 |
| Loffredo, A | 1 |
| Preiss, D | 1 |
| Sattar, N | 1 |
| Robinson, JG | 1 |
| Wang, S | 1 |
| Smith, BJ | 1 |
| Jacobson, TA | 2 |
| Nair, AP | 1 |
| Darrow, B | 1 |
| Guthrie, RM | 1 |
| Thompson, PD | 1 |
| Kole, LA | 1 |
| Ruiz, J | 1 |
| Taskinen, MR | 1 |
| Després, JP | 1 |
| Lemieux, I | 1 |
| Robins, SJ | 1 |
| Spratt, KA | 1 |
| Denke, MA | 2 |
| Birjmohun, RS | 1 |
| Hutten, BA | 1 |
| Kastelein, JJ | 2 |
| Stroes, ES | 1 |
| Caslake, MJ | 1 |
| Packard, CJ | 1 |
| Han, SH | 1 |
| Quon, MJ | 1 |
| Koh, KK | 1 |
| Császár, A | 1 |
| Davidson, MH | 1 |
| Barter, PJ | 1 |
| Rye, KA | 1 |
| Backes, JM | 1 |
| Gibson, CA | 1 |
| Ruisinger, JF | 1 |
| Moriarty, PM | 1 |
| Miller, M | 1 |
| Schaefer, EJ | 1 |
| Collins, P | 1 |
| Kodama, S | 1 |
| Sone, H | 1 |
| Kohro, T | 1 |
| Hayashi, D | 1 |
| Okada, Y | 1 |
| Yamazaki, T | 1 |
| Nagai, R | 1 |
| Abdel-Maksoud, M | 1 |
| Sazonov, V | 1 |
| Gutkin, SW | 1 |
| Hokanson, JE | 1 |
| Marín Plaza, R | 1 |
| Díaz González, JM | 1 |
| Varela de Seijas, JR | 1 |
| Cadierno Carpintero, M | 1 |
| Emeterio Reig, E | 1 |
| Soler Masana, JM | 1 |
| Sailer, D | 1 |
| Kolb, S | 1 |
| Schubotz, R | 1 |
| Schneider, J | 1 |
| Hausmann, L | 1 |
| Mühlfellner, G | 1 |
| Mühlfellner, O | 1 |
| Kaffarnik, H | 1 |
| Schonfeld, G | 1 |
| Lozada, A | 1 |
| Dujovne, CA | 1 |
| Kontopoulos, AG | 2 |
| Athyros, VG | 2 |
| Papageorgiou, AA | 2 |
| Hatzikonstandinou, HA | 1 |
| Mayroudi, MC | 1 |
| Boudoulas, H | 1 |
| Spósito, AC | 2 |
| Caramelli, B | 1 |
| Serrano, CV | 1 |
| Mansur, AP | 1 |
| Ramires, JA | 2 |
| Maranhão, RC | 1 |
| Vinagre, CG | 1 |
| Santos, RD | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Hanefeld, M | 1 |
| Fischer, S | 1 |
| Schmechel, H | 1 |
| Rothe, G | 1 |
| Schulze, J | 1 |
| Dude, H | 1 |
| Schwanebeck, U | 1 |
| Julius, U | 1 |
20 reviews available for clofibric acid and Coronary Heart Disease
| Article | Year |
|---|---|
Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Clofibric Acid; Coronary D | 2009 |
Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Female; Humans; Hydroxymethylg | 2009 |
Lipid management in the geriatric patient.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Coronary Disea | 2009 |
LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Controlled Clinical Trials as | 2003 |
Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
Topics: Anticholesteremic Agents; Clofibric Acid; Coronary Disease; Humans; Lipoproteins; Risk Factors | 2004 |
Coadministration of multidrug therapy to achieve lipid goals.
Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Coronary Disease; Drug Therapy, Combination; E | 2004 |
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Femal | 2005 |
Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Biomarkers; Clofibric Acid; Coronary Disease; Enzyme | 2005 |
Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators.
Topics: Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Huma | 2005 |
Hypertriglyceridemia, the coronary heart disease risk marker "solved".
Topics: Apolipoprotein C-III; Apolipoproteins C; Clinical Trials as Topic; Clofibric Acid; Coronary Disease; | 2005 |
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Dr | 2006 |
Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?
Topics: Cardiotonic Agents; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Gemfibrozil; Humans; | 2006 |
Fibrates: what have we learned in the past 40 years?
Topics: Clinical Trials as Topic; Clofibric Acid; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutar | 2007 |
Hypertriglyceridemia and cardiovascular risk reduction.
Topics: Atherosclerosis; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Fatty Acids, Omega-3; Hu | 2007 |
HDL-C in post-menopausal women: An important therapeutic target.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Disease; Drug Therapy, Combinat | 2008 |
[Intervention study for elevating high density lipoprotein cholesterol level].
Topics: Cholesterol, HDL; Clofibric Acid; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2007 |
Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Diabetes Complications; Humans | 2008 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fib | 1994 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Dru | 1994 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
7 trials available for clofibric acid and Coronary Heart Disease
| Article | Year |
|---|---|
[Clinical trial of a new drug for the treatment of atherosclerosis: pirozadil (722-D) (author's transl)].
Topics: Clinical Trials as Topic; Clofibric Acid; Coronary Disease; Female; Humans; Hypercholesterolemia; Hy | 1982 |
[A double blind study of the new hypolipidemic agent pirozadil (722-D) using patients with ischemic heart disease (author's transl)].
Topics: Aged; Clinical Trials as Topic; Clofibric Acid; Coronary Disease; Double-Blind Method; Female; Human | 1982 |
Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Topics: Adult; Analysis of Variance; Clofibric Acid; Coronary Disease; Double-Blind Method; Drug Therapy, Co | 1996 |
Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Disease; Delayed-Action Prepara | 1999 |
Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease.
Topics: Anticholesteremic Agents; Biomarkers; Cholesterol; Cholesterol, HDL; Chylomicrons; Clofibric Acid; C | 2001 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfib | 2001 |
Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.
Topics: Adult; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Diabeti | 1991 |
11 other studies available for clofibric acid and Coronary Heart Disease
| Article | Year |
|---|---|
Diabetic dyslipidemia: a practical guide to therapy.
Topics: Clofibric Acid; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; | 2008 |
Reshaping the dyslipidemia management paradigm.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Dyslipidemias; Fe | 2003 |
CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management.
Topics: Adult; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Diabetes Complications; Dyslipidemias; Fe | 2003 |
[Significance of HDL cholesterol increase for the risk reduction. Methods of intervention. recommendations of experts].
Topics: Acyl Coenzyme A; Adult; Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Disease | 2005 |
Lipid disorders.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary D | 2009 |
[On behalf and the extent of evidence].
Topics: Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, | 2010 |
Utility of currently available modes of therapy in reaching lipid goals.
Topics: Anticholesteremic Agents; Clofibric Acid; Coronary Disease; Fish Oils; Humans; Hydroxymethylglutaryl | 2004 |
Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric | 2005 |
Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium Cha | 2007 |
[Treatment of coronary heart disease with diet and lipid-reducing agents].
Topics: Adolescent; Adult; Child; Cholestyramine Resin; Clofibrate; Clofibric Acid; Colestipol; Coronary Dis | 1982 |
Clinical experience with bezafibrate.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; | 1980 |